WO2005094188A2 - 侵襲管理方法及びアディポネクチンの利用 - Google Patents
侵襲管理方法及びアディポネクチンの利用 Download PDFInfo
- Publication number
- WO2005094188A2 WO2005094188A2 PCT/JP2005/006395 JP2005006395W WO2005094188A2 WO 2005094188 A2 WO2005094188 A2 WO 2005094188A2 JP 2005006395 W JP2005006395 W JP 2005006395W WO 2005094188 A2 WO2005094188 A2 WO 2005094188A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adiponectin
- stress
- neutralizing agent
- blood
- endotoxin
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
Definitions
- Adiponectin is an adipose tissue-specific endocrine factor cloned by the inventor at the Center for Cell Engineering, Osaka University (Maeda K et al .: Biochem Biophys Res Commun 221 (2): 286-9, 1996). . Its blood concentration is low for those who have a low level of adiponectin, and even if the degree of obesity is the same, blood adiponectin is low due to atherosclerotic diseases such as myocardial infarction and angina, and diabetes. (Kazuhisa Maeda et al .: Annual Review 2004 Endocrinology and metabolism pi 5-19). Therefore, it is considered that adiponectin is also effective for grasping the general condition before and after surgery in patients with so-called metabolic syndrome such as diabetes, hypertension and hyperlipidemia.
- the prophylactic administration of an antibacterial agent after surgery is basically limited to the day of surgery and the day after surgery in Europe and the United States, but is often administered for several days in Japan.
- infection when infection is suspected, it can take several days for bacterial culture results to be obtained, and the administration of antimicrobial agents is often continued until then.
- large-scale clinical trials have been started at several university hospitals to determine whether SLP levels can be measured the day after surgery and used as an indicator of whether or not to continue antibiotic administration. SLP is thus being used to predict postoperative infection.
- the human adiponectin according to the present invention is used as various forms of preparations. Specifically, the strength of injections, suspensions, suppositories, ointments, creams, gels, patches, inhalants and the like is not particularly limited. Particularly, in the case of an injection, it is prepared by dissolving human adiponectin in an appropriate solvent, but a buffer or a preservative may be added.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Ecology (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES05727482T ES2365923T3 (es) | 2004-03-31 | 2005-03-31 | Uso de adiponectina como marcador en la predicción de infección postoperatoria. |
JP2006511829A JP4771940B2 (ja) | 2004-03-31 | 2005-03-31 | 侵襲管理方法及びアディポネクチンの利用 |
AT05727482T ATE515699T1 (de) | 2004-03-31 | 2005-03-31 | Verwendung von adiponectin als marker in der vorhersage post-operativer infektion |
KR1020117024465A KR20110128941A (ko) | 2004-03-31 | 2005-03-31 | 침습 관리 방법 및 아디포넥틴의 이용 |
EP05727482A EP1744160B1 (en) | 2004-03-31 | 2005-03-31 | Use of adiponectin as marker in the prediction of post-operative infection |
CNA2005800177180A CN1969187A (zh) | 2004-03-31 | 2005-03-31 | 侵袭控制方法和脂联素的利用 |
KR1020067022439A KR101223355B1 (ko) | 2004-03-31 | 2005-03-31 | 침습 관리 방법 및 아디포넥틴의 이용 |
US11/547,169 US20080139468A1 (en) | 2004-03-31 | 2005-03-31 | Method For Control of Invasion and Use of Adiponectin |
US13/890,697 US9341634B2 (en) | 2004-03-31 | 2013-05-09 | Method for controlling post-operative sepsis infection by administering adiponectin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-134823 | 2004-03-31 | ||
JP2004-134824 | 2004-03-31 | ||
JP2004134823 | 2004-03-31 | ||
JP2004134824 | 2004-03-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/547,169 A-371-Of-International US20080139468A1 (en) | 2004-03-31 | 2005-03-31 | Method For Control of Invasion and Use of Adiponectin |
US13/890,697 Continuation US9341634B2 (en) | 2004-03-31 | 2013-05-09 | Method for controlling post-operative sepsis infection by administering adiponectin |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005094188A1 WO2005094188A1 (ja) | 2005-10-13 |
WO2005094188A2 true WO2005094188A2 (ja) | 2005-10-13 |
WO2005094188A3 WO2005094188A3 (ja) | 2005-12-08 |
Family
ID=35064193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006395 WO2005094188A2 (ja) | 2004-03-31 | 2005-03-31 | 侵襲管理方法及びアディポネクチンの利用 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20080139468A1 (ja) |
EP (2) | EP1744160B1 (ja) |
JP (2) | JP4771940B2 (ja) |
KR (2) | KR101223355B1 (ja) |
CN (1) | CN1969187A (ja) |
AT (2) | ATE544467T1 (ja) |
ES (1) | ES2365923T3 (ja) |
WO (1) | WO2005094188A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1744160B1 (en) | 2004-03-31 | 2011-07-06 | Kazuhisa Maeda | Use of adiponectin as marker in the prediction of post-operative infection |
JP5432567B2 (ja) * | 2008-04-16 | 2014-03-05 | 花王株式会社 | アディポネクチン分泌調節剤の評価又は選択方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6135473A (ja) * | 1984-07-27 | 1986-02-19 | Konishiroku Photo Ind Co Ltd | 複写機における記録紙案内装置 |
DE4237502A1 (de) * | 1992-11-06 | 1994-05-11 | Biometec Ges Fuer Bio Medizini | Arzneimittel enthaltend Antiidiotyp-Antikörper gegen Anti-CD14-Antikörper |
JP3018186B1 (ja) | 1999-03-09 | 2000-03-13 | 大阪大学長 | 抗炎症剤、単球系細胞の増殖抑制剤 |
AU785090B2 (en) * | 2000-01-14 | 2006-09-14 | Serono Genetics Institute S.A. | OBG3 globular head and uses thereof for decreasing body mass |
AU2002328630B2 (en) | 2001-08-17 | 2005-09-01 | Fujirebio Inc. | Method of diagnosing or monitoring saccharometabolic error |
CA2468619A1 (en) * | 2001-12-21 | 2003-07-10 | Maxygen Aps | Adiponectin fragments and conjugates |
JP2005535561A (ja) * | 2002-01-18 | 2005-11-24 | プロテミックス コーポレイション リミティド | アディポネクチンのグリコアイソフォームとその使用 |
WO2004022596A1 (en) * | 2002-09-05 | 2004-03-18 | Komed Co., Ltd. | Monoclonal antibody against adiponectin, preparation method and use thereof |
EP1744160B1 (en) | 2004-03-31 | 2011-07-06 | Kazuhisa Maeda | Use of adiponectin as marker in the prediction of post-operative infection |
-
2005
- 2005-03-31 EP EP05727482A patent/EP1744160B1/en active Active
- 2005-03-31 ES ES05727482T patent/ES2365923T3/es active Active
- 2005-03-31 WO PCT/JP2005/006395 patent/WO2005094188A2/ja active Application Filing
- 2005-03-31 AT AT10185392T patent/ATE544467T1/de active
- 2005-03-31 US US11/547,169 patent/US20080139468A1/en not_active Abandoned
- 2005-03-31 CN CNA2005800177180A patent/CN1969187A/zh active Pending
- 2005-03-31 KR KR1020067022439A patent/KR101223355B1/ko not_active IP Right Cessation
- 2005-03-31 AT AT05727482T patent/ATE515699T1/de not_active IP Right Cessation
- 2005-03-31 KR KR1020117024465A patent/KR20110128941A/ko not_active Application Discontinuation
- 2005-03-31 EP EP10185392A patent/EP2279745B1/en not_active Not-in-force
- 2005-03-31 JP JP2006511829A patent/JP4771940B2/ja active Active
-
2011
- 2011-01-11 JP JP2011003377A patent/JP2011121959A/ja active Pending
-
2013
- 2013-05-09 US US13/890,697 patent/US9341634B2/en active Active
Non-Patent Citations (2)
Title |
---|
KELLER P; MOLLER K; KRABBE KS; PEDERSEN BK: "Circulating adiponectin levels during human endotoxaemia", CLIN. EXP. IMMUNOL., vol. 134, 2003, pages 107 - 110 |
TANOWITZ HB; MUKHERJEE S; ZHAO D; BRAUNSTEIN VB; COMBS TP; SCHERER P, AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 69, no. 3, 2003, pages 289 |
Also Published As
Publication number | Publication date |
---|---|
WO2005094188A3 (ja) | 2005-12-08 |
ATE544467T1 (de) | 2012-02-15 |
EP1744160B1 (en) | 2011-07-06 |
EP1744160A4 (en) | 2008-05-21 |
ATE515699T1 (de) | 2011-07-15 |
JPWO2005094188A1 (ja) | 2008-02-14 |
JP4771940B2 (ja) | 2011-09-14 |
JP2011121959A (ja) | 2011-06-23 |
US20080139468A1 (en) | 2008-06-12 |
EP2279745A2 (en) | 2011-02-02 |
US20130302833A1 (en) | 2013-11-14 |
EP2279745B1 (en) | 2012-02-08 |
KR20110128941A (ko) | 2011-11-30 |
US9341634B2 (en) | 2016-05-17 |
KR20070026485A (ko) | 2007-03-08 |
CN1969187A (zh) | 2007-05-23 |
EP1744160A2 (en) | 2007-01-17 |
KR101223355B1 (ko) | 2013-01-16 |
EP2279745A3 (en) | 2011-02-16 |
ES2365923T3 (es) | 2011-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver | |
Valore et al. | Antimicrobial components of vaginal fluid | |
Sugimoto et al. | IL-9 blockade suppresses silica-induced lung inflammation and fibrosis in mice | |
JP2009501521A (ja) | 炎症応答を診断および処置する方法 | |
Zumbach et al. | Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus | |
Thomson et al. | A novel primate model of delayed wound healing in diabetes: dysregulation of connective tissue growth factor | |
Carrizo et al. | Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion | |
EP2673640B1 (de) | Detektion und entfernung von missgefalteten proteinen/peptiden | |
Perks et al. | DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics | |
JP2002512259A (ja) | 組換えヘパリン結合性上皮成長因子様成長因子(hb−egf)による間質性膀胱炎の治療方法 | |
US20230414717A1 (en) | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) | |
Nakagami et al. | Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents | |
Kölmel et al. | Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension | |
WO2005094188A2 (ja) | 侵襲管理方法及びアディポネクチンの利用 | |
Gustafsson et al. | LPS interactions with immobilized and soluble antimicrobial peptides | |
EP4125988A1 (en) | Detection and treatment of intestinal fibrosis | |
JP2017530954A (ja) | トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用 | |
Christ-Crain et al. | Procalcitonin on the dusty way to the holy grail: a progress report | |
Cavassan et al. | Seeking candidate molecules as prognostic healing markers in chronic venous ulcers | |
Srivastava et al. | Expression of antimicrobial peptides and cytokines in human omentum following abdominal surgery | |
JP2023524604A (ja) | 虚弱を処置するためのゲルソリンを含む組成物 | |
KR20230019780A (ko) | 히스톤 펩타이드를 유효성분으로 포함하는 관절염 진단용 조성물 | |
JP2005527813A (ja) | βig−h3蛋白質の定量方法及びこれを利用した診断キット | |
Singhal | Correlation of Soluble Receptor for Advanced Glycation End Products (sRAGE) and Tumor Necrosis Factor-Alpha (TNF-α) Levels in Crevicular Fluid and Serum in Chronic Periodontitis Subjects with and Without Type 2 Diabetes Mellitus | |
GOUT | shown zyxwvutsrqponm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006511829 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067022439 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727482 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580017718.0 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727482 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067022439 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11547169 Country of ref document: US |